Reducing Prescription Drug Costs for Connecticut Residents
Prescription drug costs continue to be one of the fastest-growing expenses for Connecticut families, seniors, and individuals living with chronic health conditions. During the 2025 legislative session, Connecticut House Democrats passed HB 7192 to lower prescription drug costs, increase transparency, and ensure consumers, not middlemen, benefit from manufacturer discounts.
The legislation reforms the practices of pharmacy benefit managers (PBMs), requires prescription drug rebates to be passed directly to consumers, and begins the process of allowing lower-cost prescription drug imports from Canada.
Together, these reforms help make prescription medications more affordable while increasing accountability throughout the pharmaceutical supply chain.
Stopping Pharmacy Benefit Managers from Driving Up Costs
Pharmacy benefit managers (PBMs) play a major role in negotiating prescription drug prices between drug manufacturers, insurance companies, and pharmacies.
However, certain PBM business practices have contributed to higher costs for consumers.
HB 7192 prohibits pharmacy benefit managers from passing along prescription drug cost increases when those increases primarily benefit the PBM rather than patients.
The reforms help:
- Increase pricing transparency
- Reduce unnecessary prescription costs
- Improve accountability throughout the prescription drug supply chain
- Put consumers ahead of corporate middlemen
Ensuring Drug Manufacturer Rebates Benefit Consumers
Drug manufacturers often provide rebates to pharmacy benefit managers and insurers.
Historically, consumers have not always received the financial benefit of these discounts.
HB 7192 requires qualifying prescription drug rebates to be passed directly to consumers, helping lower out-of-pocket costs at the pharmacy counter.
Passing rebates directly to patients helps:
- Reduce prescription drug expenses
- Lower out-of-pocket costs
- Improve medication affordability
- Increase transparency in prescription pricing
Exploring Lower-Cost Prescription Drugs from Canada
The legislation also takes initial regulatory steps toward allowing Connecticut to pursue prescription drug importation from Canada, subject to applicable federal approvals.
Many prescription medications are sold at significantly lower prices in Canada than in the United States.
By beginning the regulatory process, Connecticut aims to explore safe opportunities to increase competition and reduce prescription drug costs for residents while maintaining federal safety standards.
Increasing Transparency Throughout the Drug Supply Chain
Prescription drug pricing often involves multiple organizations, including manufacturers, wholesalers, pharmacy benefit managers, insurers, and pharmacies.
HB 7192 improves transparency by reducing opportunities for hidden pricing practices that contribute to higher consumer costs.
Greater accountability helps patients better understand how prescription drug prices are determined while encouraging fairer market practices.
Helping Connecticut Families Afford Essential Medications
For many Connecticut residents, prescription medications are essential to managing chronic illnesses, preventing disease, and maintaining quality of life.
Lowering prescription drug costs can help families:
- Better manage household budgets
- Improve medication adherence
- Reduce financial barriers to healthcare
- Improve long-term health outcomes
Affordable medications help ensure patients receive the treatments they need without delaying care because of cost.
Building a More Affordable Healthcare System
HB 7192 represents another step toward making healthcare more affordable by addressing one of the largest drivers of out-of-pocket medical expenses.
By increasing transparency, limiting unnecessary costs, ensuring rebates benefit consumers, and exploring lower-cost medication options, Connecticut is working to make prescription drugs more accessible for patients across the state.
Frequently Asked Questions
What does HB 7192 do?
HB 7192 lowers prescription drug costs by reforming pharmacy benefit manager practices, requiring certain drug manufacturer rebates to be passed directly to consumers, and beginning the process of exploring prescription drug importation from Canada.
What is a pharmacy benefit manager (PBM)?
A pharmacy benefit manager is a company that administers prescription drug benefits on behalf of health insurers and employers by negotiating with drug manufacturers and pharmacies.
How do rebate reforms help consumers?
The legislation requires qualifying manufacturer rebates to benefit consumers directly, helping lower out-of-pocket prescription drug costs rather than allowing rebates to remain with intermediaries.
Why is Connecticut exploring prescription drug imports from Canada?
Many prescription medications cost less in Canada. The legislation begins the regulatory process needed to pursue safe importation options, subject to federal approval, with the goal of increasing competition and reducing prices.
How do these reforms lower healthcare costs?
By increasing pricing transparency, limiting unnecessary markups, ensuring rebates reach consumers, and exploring lower-cost drug purchasing options, the legislation helps reduce prescription drug expenses for Connecticut families.
Who benefits from these reforms?
Patients with chronic health conditions, seniors, working families, employers, and anyone who relies on prescription medications can benefit from lower costs and greater transparency.